CXCL4 drives fibrosis by promoting several key cellular and molecular processes

0301 basic medicine Epithelial-Mesenchymal Transition systemic sclerosis Pulmonary Fibrosis General Biochemistry,Genetics and Molecular Biology Platelet Factor 4 Cell Line Bleomycin Mice 03 medical and health sciences SDG 3 - Good Health and Well-being Human Umbilical Vein Endothelial Cells Animals Humans Myofibroblasts Lung Mice, Knockout Mice, Inbred BALB C Scleroderma, Systemic bleomycin fibrosis Endothelial Cells CXCL4 myofibroblast endothelial-to-mesenchymal transition Extracellular Matrix 3. Good health Mice, Inbred C57BL Disease Models, Animal inflammation Collagen Pericytes
DOI: 10.1016/j.celrep.2021.110189 Publication Date: 2022-01-04T15:45:29Z
ABSTRACT
Fibrosis is a major cause of mortality worldwide, characterized by myofibroblast activation and excessive extracellular matrix deposition. Systemic sclerosis is a prototypic fibrotic disease in which CXCL4 is increased and strongly correlates with skin and lung fibrosis. Here we aim to elucidate the role of CXCL4 in fibrosis development. CXCL4 levels are increased in multiple inflammatory and fibrotic mouse models, and, using CXCL4-deficient mice, we demonstrate the essential role of CXCL4 in promoting fibrotic events in the skin, lungs, and heart. Overexpressing human CXCL4 in mice aggravates, whereas blocking CXCL4 reduces, bleomycin-induced fibrosis. Single-cell ligand-receptor analysis predicts CXCL4 to affect endothelial cells and fibroblasts. In vitro, we confirm that CXCL4 directly induces myofibroblast differentiation and collagen synthesis in different precursor cells, including endothelial cells, by stimulating endothelial-to-mesenchymal transition. Our findings identify a pivotal role of CXCL4 in fibrosis, further substantiating the potential role of neutralizing CXCL4 as a therapeutic strategy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (98)
CITATIONS (52)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....